Lipocut 60 Capsule contains Orlistat 60 mg, a potent lipase inhibitor indicated for the management of obesity. It acts by selectively inhibiting gastrointestinal lipases, thereby reducing the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. This mechanism results in decreased fat absorption by approximately 30%, promoting weight loss when combined with a mildly hypocaloric diet. Lipocut 60 is prescribed for overweight and obese patients with a body mass index (BMI) of 28 kg/m² or higher, particularly those with associated risk factors such as hypertension, dyslipidemia, or type 2 diabetes mellitus. The recommended dosage is one capsule taken orally three times daily with each main meal containing fat. Adherence to a balanced, reduced-calorie diet is essential to optimize therapeutic outcomes and minimize gastrointestinal adverse effects, which may include oily spotting, flatulence with discharge, and fecal urgency. Lipocut 60 should be used under medical supervision, with regular monitoring of liver function and fat-soluble vitamin levels, as Orlistat may impair absorption of vitamins A, D, E, and K. It is contraindicated in patients with chronic malabsorption syndrome or cholestasis. Lipocut 60 Capsule offers an effective adjunctive treatment for weight management in appropriate patients, supporting improved metabolic health and reduced obesity-related complications.